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Background: It was hypothesized that a mobile health (mHealth) intervention would elicit greater improvements in
systolic blood pressure and other cardiometabolic risk factors at 12 weeks, which would be better maintained over
52 weeks, compared to the active control intervention.
Methods: Eligible participants (≥2 metabolic syndrome risk factors) were randomized to the mHealth intervention
(n = 75) or the active control group (n = 74). Blood pressure and other cardiometabolic risk factors were measured
at baseline and at 12, 24 and 52 weeks. Both groups received an individualized exercise prescription and the
intervention group additionally received a technology kit for home monitoring of biometrics and physical activity.
Results: Analyses were conducted on 67 participants in the intervention group (aged 56.7 ± 9.7 years; 71.6%
female) and 60 participants in the active control group (aged 59.1 ± 8.4 years; 76.7% female). At 12 weeks, baseline
adjusted mean change in systolic blood pressure (primary outcome) was greater in the active control group
compared to the intervention group (-5.68 mmHg; 95% CI -10.86 to -0.50 mmHg; p = 0.03), but there were no
differences between groups in mean change for secondary outcomes. Over 52-weeks, the difference in mean
change for systolic blood pressure was no longer apparent between groups, but remained significant across the
entire population (time: p < 0.001).
Conclusions: In participants with increased cardiometabolic risk, exercise prescription alone had greater short-term
improvements in systolic blood pressure compared to the mHealth intervention, though over 52 weeks,
improvements were equal between interventions.
Trial registration: ClinicalTrials.gov NCT01944124
Keywords: Mobile health, Metabolic syndrome, Exercise prescription, Exercise intervention, Disease prevention,
Rural healthBackground
Cardiovascular diseases are the leading cause of morbidity
and mortality world-wide [1] and patients with type 2
diabetes are at a high risk of developing cardiovascular
complications. Metabolic syndrome is a clustering of
risk factors that increases the risk of developing type 2
diabetes and cardiovascular diseases [2,3]. Recent re-
ports have shown that the prevalence of cardiovascular
diseases, type 2 diabetes [4,5] and metabolic syndrome* Correspondence: petrella@uwo.ca
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unless otherwise stated.[6] is higher in rural compared to urban settings. Much
of the disparity is associated with demographic and
behavioral factors associated with rural living [4,6].
Evidence suggests that lifestyle interventions aimed at
controlling cardiometabolic risk factors can reduce the
incidence of type 2 diabetes [7,8], but access to health-
care and lifestyle change programs is limited in rural
communities. Novel interventions aimed at improving
short-term uptake and long-term maintenance of such
programs are needed for this population.
Mobile health (mHealth) has the potential to reach
broad populations and may provide the opportunity to
support lifestyle changes in rural populations. A number
of studies have shown that mHealth is effective in the
self-management of type 2 diabetes [9] and hypertensionLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
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mHealth added to a hypertension management program
showed improvements in both mHealth intervention
and active control groups but greater improvements in
BP in the mHealth intervention group [11]. These find-
ings suggest that mHealth may have additional benefits
when added to an existing treatment program; however,
the use of mHealth to enhance exercise therapy has not
been examined. Management of cardiometabolic risk
factors prior to disease onset may have the potential to
reduce disease burden. To date, however, evidence sup-
porting the use of mHealth technologies for disease pre-
vention is sparse. We recently completed a pilot study,
which demonstrated that an intervention aimed at in-
creasing physical activity while using mHealth technolo-
gies to monitor biometrics, improved diastolic blood
pressure (DBP), total cholesterol and physical fitness
over an eight-week period [12]. It remains unknown
whether the mHealth tracking provided any added bene-
fit over the exercise intervention alone and whether the
improvements would be maintained over a longer follow-
up period. The findings from this pilot study along with
participant and clinician feedback was used to develop the
intervention for the present study.
The purpose of this study was two-fold: first, to investi-
gate the effects of a mHealth supported exercise interven-
tion compared to an active control group receiving only
the exercise prescription over a short-term (12-week)
period; and second, to examine the long-term mainten-
ance over 24 and 52 weeks of follow-up. The primary
hypothesis was that the intervention group receiving
mHealth support would have greater reductions in sys-
tolic blood pressure (SBP) and other cardiometabolic
risk factors at 12 weeks compared to the active control
group. Secondary hypotheses were that the mHealth
intervention group would also have greater decreases in
DBP, waist circumference, lipids (with the exception of
high density lipoprotein cholesterol (HDL), which was
expected to increase) and markers for blood glucose
and inflammation compared to the active control group.
It was hypothesized that all improvements would be
better maintained over the 52-week follow-up period in
the intervention group compared to the active control
group.
Methods
Full details of the study protocol have been previously
published [13]. Community-dwelling adults aged 18-
70 years from Huron-Perth and Grey-Bruce counties
(Ontario, Canada) were recruited via print and radio
advertisements, word of mouth, community presentations
and physician referral. Participants with at least two meta-
bolic syndrome risk factors as defined by the National
Cholesterol Education Program Adult Treatment Panel III[waist circumference ≥88 cm (women) or 102 cm (men);
SBP ≥135 mmHg and/or DBP ≥85 mmHg; fasting plasma
glucose ≥6.1 mmol/L; fasting triglycerides ≥1.7 mmol/L;
fasting HDL ≤1.29 mmol/L (women) or 1.02 mmol/L
(men)] [14] presented to a community-based research
centre (Gateway Rural Health Research Institute, Seaforth,
Ontario, Canada) and voluntarily provided informed con-
sent to participate in this parallel-group, randomized con-
trolled trial (ClinicalTrials.gov NCT01944124). Exclusion
criteria, evaluated by self-report during a screening phone
call and verified in-person were: SBP >180 mmHg and/or
DBP >110 mmHg; type 1 diabetes; history of myocardial
infarction, angioplasty, coronary artery bypass or cerebro-
vascular ischemia; symptomatic congestive heart failure;
atrial flutter; unstable angina; unstable pulmonary disease;
use of medications known to affect heart rate; second or
third degree heart block; history of alcoholism, drug abuse
or other emotional cognitive or psychiatric problems;
pacemaker; unstable metabolic disease; and orthopedic
or rheumatologic problems that could impair the ability
to exercise. This study was approved by the Western
University Health Sciences Research Ethics Board
(Protocol # 15828).
Participants (n = 149) were randomly assigned (1:1
allocation) to the mHealth supported exercise interven-
tion group or the active control group. To accommodate
deployment and activation of technology and implementa-
tion of technology training sessions, randomization was
blocked based on appointment time, such that all par-
ticipants attending appointments during week 1 were
randomized to the intervention group, those attending
appointments during week 2 were randomized to the
control group, and so on. Due to this randomization
procedure, research staff could not be blinded to group
allocation. At baseline and at 12, 24, and 52 weeks of
follow-up, participants reported to the clinic for assess-
ment following a minimum eight-hour fast. Waist cir-
cumference was measured at the mid-point between
the twelfth rib and upper border of the iliac crest fol-
lowing normal expiration. Supine blood pressure was
measured with an automated sphygmomanometer (BPTru®,
Coquitlam, Canada) following a five-minute rest period.
Blood was drawn and sent to a central laboratory for ana-
lysis of fasting plasma glucose, triglycerides, cholesterol,
glycated hemoglobin (HbA1C), insulin and high sensitivity
C-reactive protein (CRPhs; a biomarker, which is increased
with systemic inflammation). Insulin resistance was calcu-
lated using the Homeostatis Model Assessment for Insulin
Resistance (HOMA-IR) [15].
Following a light, standardized snack, participants’
fitness was assessed and a tailored exercise program was
prescribed by an exercise specialist according to the Step
Test and Exercise Prescription (STEP™) protocol [16,17].
Aerobic exercise was prescribed on most days of the week
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85% of an estimated maximum heart rate for those whose
fitness was classified as poor, good, very good or excellent,
respectively. Participants were to accumulate 30 to 60 mi-
nutes of exercise per day with bouts of at least 10 minutes
each. Resistance training was prescribed two to four times
per week. The exercise prescription was updated at 12 and
24 weeks. While the exercise specialist ensured that the
exercise prescription complied with current global phys-
ical activity guidelines, which are recommended for opti-
mal general health, including blood pressure control [18]
(i.e., 150 minutes per week of moderate-to-vigorous inten-
sity exercise), during the exercise counselling session, par-
ticipants self-selected goals that were important to them.
This was done in an attempt to motivate participants to
adhere to the program to reach their own personal goals
rather than attempting to encourage them with our pre-
determined study goals. Participants were instructed to
record all planned exercise sessions. Participants in the
intervention group logged exercise using mHealth tools
(described below) and the active control group logged ex-
ercise in a paper journal.
In addition to the exercise prescription, participants in
the mHealth intervention group received a kit, which
included a smartphone data portal (Blackberry® Curve
8300 or 8530) equipped with Healthanywhere health
monitoring application (Biosign Technologies Inc.,
Markham, Ontario, Canada), a Bluetooth™ enabled blood
pressure monitor (A & D Medical, UA-767PBT, San Jose,
California, USA), a glucometer (Lifescan One Touch
Ultra2™, Milpitas, California, USA) with Bluetooth™
adapter (Polymap Wireless, PWR-08-03, Tucson, Arizona,
USA) and a pedometer (Omron, HJ-150, Kyoto, Japan)
(Figure 1). The mHealth technologies were provided







Figure 1 Mobile health technologies. Solid line = flow of information; do
Bluetooth® connection; dashed line = measurement manually inputted to sa two-hour session, during which they learned how to
use the technologies; were provided with information
regarding normal values for fasting glucose, blood pres-
sure and pedometer steps; and were encouraged to use
the technologies to monitor their own health. Partici-
pants contacted research staff for troubleshooting as
needed, but they did not receive additional lifestyle
coaching compared to the active control group. The
home-monitoring protocol required participants to in-
put pedometer steps and exercise daily; measure blood
pressure and fasting blood glucose three times per
week; and measure body weight with their own home
scale once per month. When measurements were out-
side of pre-determined safety limits, an automated alert
was sent to the study physician’s smartphone for follow-
up. Full details of database security, automated alerts
and follow-up are reported elsewhere [13].
Statistical analysis
The sample size was calculated based on an estimated
difference in mean change between the intervention and
active control groups in SBP (primary outcome measure)
of 6 mmHg at 12 weeks. A common standard deviation
of 12 mmHg was assumed. The sample size calculation
assumed 80% power and two-sided significance level of
0.05. It was determined that 63 participants would be re-
quired per group and by assuming a 15% drop-out rate,
the required sample size increased to 73 participants per
group. Secondary outcomes were DBP, waist circumfer-
ence, fasting plasma glucose, HbA1C, triglycerides, HDL,
low density lipoprotein cholesterol (LDL), total choles-
terol, HOMA-IR and CRPhs. An a priori decision was
made to require a minimum of two data points (i.e., data
from baseline visit and at least one follow-up visit) to




tted line =measurement transmitted from device to smartphone via
martphone.
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and/or 52 weeks) were included in the analyses (n =127).
Last observation carried forward was used to impute
missing data. For our primary analysis (12-week analysis
for SBP), 2% of participants had their data carried for-
ward from baseline. These participants had missed their
12-week visit but since they attended either the 24 and/
or 52-week visit, data was carried forward from baseline
(to 12-weeks) in these instances. For 12-week analysis
of secondary outcomes, the proportion of participants
with data carried forward ranged from 2 to 3%. For the
longitudinal analyses, approximately 15% of participants
had data carried forward in time.
Descriptive statistics were computed for baseline
demographic and clinical characteristics at each time point
by group. Specifically, means and standard deviations were
calculated for continuous variables and frequency counts
and percentages were calculated for categorical variables.
Exercise compliance was calculated as the percentage of
weeks in which at least 150 minutes of exercise was re-
corded. Compliance to the mHealth monitoring protocol
was calculated as the percentage of measurements submit-
ted for each monitoring tool over the 52-week interven-
tion period and from weeks 1-12, 13-24 and 25-52.
Analysis of covariance was used to examine differences be-
tween groups in mean change over 12 weeks, adjusting for
baseline values. Thus, the outcome variable was change
between baseline and 12-weeks and model terms included
group and the baseline value of outcome. Two-way re-
peated measures ANOVA was used to extend the 12-week
analyses to include data collected at all time-points, for
each outcome of interest [i.e., four measurements in total,
one corresponding to each time point, were included as
part of the outcome variable]. For each model (outcome),
the terms group, time, and group × time were included.
Due to non-normality, triglycerides, HOMA-IR and
CRPhs were transformed to the natural logarithm scale
for these analyses. Post-hoc comparisons were done
using the Bonferroni method. Analyses were performed
using R 3.0.1 [19].
Results
Participant flow
During the recruitment period (November 2009 to
December 2010) 238 individuals contacted the study co-
ordinator to inquire about the trial and 89 individuals were
excluded as they did not meet inclusion criteria (n = 61) or
they were not interested in participating (n = 28). The
remaining 149 individuals were randomized to either the
technology intervention group (n = 75) or the active control
group (n = 74). The flow of participants for the primary
outcome analysis is shown in Figure 2. At 12 weeks, four
participants in the intervention group and seven in the ac-
tive control group failed to attend their appointment andwere lost to follow-up. Four participants in the intervention
group chose to discontinue the intervention because they
disliked the technology intervention (n = 2), for personal
reasons (n = 1) or due to lack of time (n = 1). Seven partici-
pants in the active control group chose to discontinue the
intervention due to lack of time (n = 4) or personal reasons
(n = 3). In total, eight participants were removed from ana-
lysis in the intervention group and fourteen from the active
control group as only one data point was available (i.e.,
were lost to follow-up or withdrew from study after base-
line assessment). Thus, 67 participants were analyzed from
the intervention group and 60 participants were analyzed
from the active control group.
Over the remainder of the follow-up period, three
participants in the intervention group (n = 1 at 24 weeks;
n = 2 at 52 weeks) and six in the active control group
(n = 5 at 24 weeks; n = 1 at 52 weeks) failed to attend
their appointment and were lost to follow-up. Three
participants in the intervention group chose to discon-
tinue the intervention due to lack of time (n = 1), personal
(n = 1) or medical reasons (n = 1). Four participants in the
active control group chose to discontinue the trial due to
lack of time (n = 1), medical reasons (n = 2) or relocation
to a different region (n = 1). The trial ended as per the
protocol at the completion of the final 52-week follow up
visit.
Participant characteristics
Baseline demographic and clinical characteristics are
shown in Table 1 for all participants who were random-
ized (n = 149). In both groups, participants were on aver-
age in their mid to late 50s, three-quarters were female
and all were of Caucasian decent. At baseline, 27 (36.0%)
and 33 (44.6%) of intervention and active control partici-
pants, respectively, reported antihypertensive therapy. Of
these participants, 16 (59.3%) in the intervention group
and 21 (63.6%) were prescribed only one antihyperten-
sive medication, while the remaining were prescribed
combination therapy. The median number of days per
week of physical activity participation was 2.5 (IQR 3.5)
for the intervention group and 3.0 (IQR 4.0) for the active
control group. Average pVO2max was 30.5 (6.8) ml/kg/min
and 31.2 (6.3) ml/kg/min for the intervention and active
control groups, respectively.
We compared these baseline demographic and clinical
characteristics of the full study sample to those who
remained in our main analyses (n =127; n =67 in the inter-
vention group and n =60 in the active control group) and
noted very similar percentages and descriptive statistics
for both groups, for all characteristics.
Short-term results
At 12 weeks, adjusted mean change in SBP was greater
in the active control group compared to the intervention
Assessed for eligibility (n=238) 
Excluded (n=89) 
♦ Did not qualify (n=61) 
♦ Declined to participate (n=28) 
Analysed (n=67) 
♦ Excluded from analysis (n=8) 
♦ Drop out before 12 weeks (n=8) 
Lost to follow-up (n=4) 
Discontinued intervention (n=4) 
♦ Disliked intervention (n=2) 
♦ Personal reasons (n=1) 
♦ Lack of time (n=1) 
Allocated to intervention group (n=75) 
♦ Received allocated intervention (n=75)
Lost to follow-up (n=7) 
Discontinued intervention (n=7) 
♦ Lack of time (n=4) 
♦ Personal reasons (n=3) 
Allocated to active control group (n=74) 
♦ Received allocated intervention (n=74)
Analysed (n=60) 
♦ Excluded from analysis (n=14) 
♦ Drop out before 12 weeks (n=14) 
Randomized (n=149) 
Figure 2 Participant flow.
Petrella et al. BMC Public Health 2014, 14:1082 Page 5 of 11
http://www.biomedcentral.com/1471-2458/14/1082group (-5.68 mmHg; 95% CI -10.86 to -0.50 mmHg;
p = 0.03) (Table 2). Post-hoc comparisons (following
the two-way repeated measures ANOVAs) revealed
within group differences from 0 to 12-weeks for the
active control group only [Intervention: -2.96 (-7.48
to 1.57) mmHg, p = 0.35; Active Control: -8.73 (-13.6
to -3.91) mmHg, p < 0.001]. For all secondary outcomes
examined, there were no group differences in 12-week
mean change (Table 2). Although there were no other
differences between groups at 12-weeks, post-hoc com-
parisons revealed within group differences for both
groups from 0 to 12-weeks for DBP [Intervention: -2.58
(-4.90 to -0.27) mmHg, p = 0.02; Active Control: -4.86
(-7.33 to -2.40) mmHg, p < 0.001], and waist circumfer-
ence [Intervention: -0.87 (-1.63 to -0.11) inches, p = 0.02;
Active Control: -0.91 (-1.71 to -0.11) inches, p = 0.02].
Graphical results are displayed in Figures 3 and 4 for the
primary outcome and all secondary outcomes.
Long-term (Maintenance) results
When all time-points were considered, the difference in
mean change for SBP was no longer apparent between
the intervention and active control groups, however, the
decrease remained significant across the entire population(time: p < 0.001). Post-hoc comparisons revealed that there
were significant differences from 0 to 24 and 52 weeks
within both groups (see Figure 3 Part A, all p < 0.001). For
the secondary outcomes over the 52-week follow-up
period, there was a main effect of time for DBP, waist cir-
cumference, HbA1C, LDL, total cholesterol, and triglycer-
ides but there were no group or group × time effects.
There was a main effect for group for fasting plasma glu-
cose, HOMA-IR and CRPhs, which were all higher in the
intervention group, and there was a group × time inter-
action for fasting plasma glucose. There were no signifi-
cant effects for HDL (see Additional file 1: Table S1).
Results of post-hoc analyses for within group changes
over time and between group changes at each time point
are shown on the plots in Figures 3 and 4. DBP and
waist circumference were reduced in both intervention
and active control groups at 24 and 52 weeks compared
to baseline (all p < 0.001). There were no changes in fast-
ing plasma glucose in the intervention group, but com-
pared to baseline, fasting plasma glucose was increased at
52 weeks in the active control group (p = 0.02). At baseline
and 12-weeks, fasting plasma glucose was higher in the
intervention compared to the active control group (both
p < 0.05), but there were no differences between groups at







Age (years) 55.7 (10.1) 57.8 (8.7)
Sex (female) 55 (73.3%) 56 (75.7%)
Race (Caucasian)† 74 (100%) 73 (100%)
Smoking status:
Current 3 (4.0%) 1 (1.4%)
Former 31 (41.3%) 29 (39.2%)
History of Type 2 Diabetes 3 (4.0%) 4 (5.4%)
Antihypertensive Therapy 27 (36.0%) 33 (44.6%)
Monotherapy 16 (59.3%) 21 (63.6%)
Combination Therapy 11 (40.7%) 12 (36.3%)
Angiotensin Converting
Enzyme Inhibitors 10 (37.0%) 20 (60.6%)
Angiotensin Receptor Blockers 6 (22.2%) 10 (30.3%)
Calcium Channel Blockers 4 (14.8%) 1 (3.0%)
Diuretics 17 (63.0%) 15 (45.4%)
Alpha Receptor Blockers 1 (3.7%) 0 (0%)
Average frequency of physical activity
(in last 7 days), median (IQR)‡
2.5 (3.5) 3.0 (4.0)
pVO2max 30.5 (6.8) 31.2 (6.3)
Abbreviations: IQR interquartile range, pVO2max predicted maximal oxygen
uptake (aerobic fitness).
*Data are means (SD) or numbers (%) unless otherwise indicated. Percentages
are calculated excluding missing values.
†Missing values: Intervention (n = 1) and Active Control (n = 1).
‡Average of: (a) number days (in last 7) that at least 30 minutes of continuous
physical activity was done and b) number of days (in last 7) participated in a
specific exercise session.
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line, HbA1C was reduced in both intervention and active
control groups at 24 weeks (p < 0.05), but at 52 weeks it
remained lower than baseline only in the intervention
group (p < 0.001) (see Figure 3 Part E). At baseline, 24 and
52 weeks, HOMA-IR was higher in the intervention group
compared to the active control group (all p < 0.05), with
no differences at 12 weeks (see Figure 3 Part F). At
52 weeks, LDL was reduced in both intervention and
active control groups compared to baseline (p < 0.05),
and total cholesterol was reduced in the active control
group at 24 weeks (p = 0.04) and in both groups at
52 weeks (p < 0.01), compared to baseline (see Figure 4
Parts B and C). Triglycerides were reduced only in the
active control group at 52 weeks compared to baseline
(p = 0.005) (see Figure 4 Part D). Finally, CRPhs was
higher in the intervention group at 12 weeks (p = 0.02)
and 52 weeks (p = 0.02), with no differences at baseline
and 24 weeks (see Figure 4 Part E).Compliance to exercise prescription
Exercise compliance is presented as mean (standard de-
viation; SD). At 12 weeks, the intervention and active
control groups exercised on average 188.2 (189.5) and
170.3 (161.2) minutes per week, respectively. Exercise
compliance was 47.8% (41.2%) for the intervention
group and 46.1% (39.0%) for the active control group.
Twenty-seven (40%) participants in the intervention
group and 18 (30%) of participants in the active control
group had an exercise compliance of 75% or greater.
Compliance to mHealth Self-management protocol
Compliance is presented as mean (SD). Over the 52-
week intervention period 82.7 (21.8), 82.2 (22.2), 70.9
(28.4) and 41.5 (29.8)% of measurements were com-
pleted for BP, FPG, pedometer steps and body weight,
respectively. BP monitoring compliance decreased from
91.5 (17.4)% from weeks 1-12 to 86.7 (20.3)% from
weeks 13-24 and to 77.6 (27.5)% from weeks 25-52.
Similarly, compliance to the FPG monitoring protocol
decreased from 90.3 (17.8)% from weeks 1-12 to 87.2
(20.0)% from weeks 13-24 and to 77.0 (27.9)% from
weeks 25-52. Compliance to the activity monitoring
protocol by logging pedometer steps decreased from
83.6 (21.1)% from week 1-12 to 77.2 (28.4)% from weeks
13-24 to 63.1 (34.9)% from weeks 25-52. Body weight
measurement compliance decreased from 63.6 (31.9)%
from weeks 1-12 to 38.2 (40.4)% from weeks 13-24 and
to 28.4 (34.2)% from weeks 25-52.
Alarms
Over the 52-week intervention period, 12 alarms were
triggered from high glucose readings, with the majority
(n = 11) from a single participant who was diagnosed
with type 2 diabetes after following up with her family
physician in response to the high readings in the study.
Seven alarms were triggered from high diastolic BP
readings, one which resulted in physician follow-up
and increased medication. One alarm was triggered
from a mistakenly high heart rate reading, but none
from systolic BP.
Adverse events
Four adverse events were reported from three participants
in the active control group. Adverse events included an-
gina (n = 2), stroke (n = 1), and arm/shoulder pain (n = 1).
No adverse events were reported in the intervention
group.
Discussion
Contrary to the hypothesis, the main finding of this
study was that at 12 weeks, the reduction in SBP was
greater in the active control group compared to the
intervention group. By 52 weeks, however, the reduction
Table 2 Short-term Results: Primary and Secondary Outcomes











Estimate (95% CI) p
SBPrest, mmHg
† 141.2 (19.7) 138.2 (17.8) 141.4 (18.2) 132.7 (18.4) -5.68 (-10.86 to -0.50) 0.03
DBPrest, mmHg
† 86.5 (11.0) 84.0 (10.7) 85.8 (9.3) 80.9 (9.0) -2.55 (-5.24 to 0.13) 0.06
WC, cm 105.5 (12.8) 103.3 (12.3) 102.3 (16.6) 100.0 (16.4) -0.36 (-2.18 to 1.46) 0.69
FG, mmol/L 5.29 (1.11) 5.33 (1.03) 4.87 (0.50) 4.94 (0.51) -0.06 (-0.24 to 0.11) 0.47
HbA1c, % 5.86 (0.75) 5.80 (0.68) 5.77 (0.33) 5.75 (0.36) 0.02 (-0.07 to 0.10) 0.65
HbA1c, (mmol/mol) 41 (8.2) 40 (7.4) 40 (3.6) 39 (3.9) 0.2 (-0.8 to 1.1) 0.65
HOMA-IR‡ 2.56 (1.88) 2.38 (1.59) 1.69 (1.15) 1.92 (1.44) 0.12 (-0.30 to 0.53) 0.58
HDL, mmol/L 1.40 (0.39) 1.39 (0.40) 1.45 (0.38) 1.47 (0.38) 0.04 (-0.03 to 0.10) 0.26
LDL, mmol/L 3.14 (0.84) 3.09 (0.96) 3.24 (0.78) 3.09 (0.87) -0.08 (-0.31 to 0.15) 0.51
T-Chol, mmol/L 5.31 (1.01) 5.19 (1.09) 5.37 (0.94) 5.20 (0.98) -0.05 (-0.30 to 0.21) 0.72
TG, mmol/L 1.68 (1.45) 1.52 (0.87) 1.50 (0.70) 1.39 (0.66) -0.04 (-0.20 to 0.13) 0.67
CRPhs, mg/L 3.46 (4.59) 3.34 (3.61) 2.46 (2.64) 2.41 (3.42) -0.16 (-0.84 to 0.53) 0.65
Abbreviations: CI Confidence interval, SBPrest resting systolic blood pressure, DBPrest resting diastolic blood pressure, WC waist circumference, FG fasting glucose,
HbA1c glycated hemoglobin, HOMA-IR Homeostasis Model for Insulin Resistance, HDL high density lipoprotein cholesterol, LDL low density lipoprotein cholesterol,
T-Chol total cholesterol, TG triglycerides, CRPhs high sensitivity C-reactive protein.
*Group differences calculated as Active Control – Intervention and adjusted for baseline.
†n =59 in the active control group.
‡n =65 in the intervention group.
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groups. At 12 weeks, the mean change in all secondary
outcomes examined was similar between groups. Over
the 52-week follow up period, the improvements in DBP,
waist circumference, HbA1C, LDL and total cholesterol
were similar between groups, with no change in HDL
for either group.
This study was limited to highly motivated adults resid-
ing in rural communities who volunteered to participate
in an intensive lifestyle intervention. Therefore, findings
may not be generalizable to less motivated adults or to
those residing in urban centres. Since the study was con-
ducted in small rural communities and a considerable
amount of recruitment was accomplished by word-of-
mouth, it is likely that there was contact between partic-
ipants in the mHealth intervention and active control
groups throughout the course of the study. Social sup-
port was not controlled for and may have biased results.
The randomization procedures were pragmatically de-
signed for deployment of technology kits and activation of
smartphones and the mobile application. While a more
typical randomization procedure would have made the
study design stronger (i.e., completing randomization after
baseline assessments), it would have been impractical due
to the logistics associated with implementing the technol-
ogy component. Although the primary outcome measure
was SBP, blood pressure reduction was not necessarily the
goal of the exercise program. Rather, participants’ self-
selected goals and the exercise specialist provided guid-
ance and prescribed an exercise program to achieve thesegoals; had all participants received exercise prescriptions
based on the study goals, greater improvements may have
occurred. Tailored exercise programs, however, are gener-
ally more effective and participants may have been less
motivated to adhere to their exercise prescription if it had
not been based on their personal health goals. In fact, the
STEP™ tool has been investigated in previous randomized
clinical and observational studies and has been proved to
positively effect exercise behaviours and cardiometabolic
risk factors [17]. The STEP™ protocol requires little equip-
ment and can be easily translated to community settings.
The mHealth monitoring technology and protocol was
tested for feasibility and the development of this protocol
was guided by our previous pilot study [12,20].
Lifestyle modification is known to improve cardio-
metabolic risk status and is recommended as first line
therapy for prevention and treatment of metabolic syn-
drome [2,3,14]. Longitudinal studies have demonstrated
the efficacy of lifestyle modification interventions targeting
physical activity, diet and other behaviours to improve
metabolic syndrome risk factors [21]. Such programs,
however, are often not available to rural populations.
mHealth-supported interventions are accessible to a
broad population, including those in rural communities,
and have the potential to be delivered as sustainable
programs for behaviour modification and maintenance.
Research supports the use of electronic health, includ-
ing mHealth interventions for management of diabetes
[9] and hypertension [10,11]. Contrary to these findings,
and those of a meta-analysis that examined the effects
A. B. C. 
E.D. F. 
Intervention Active Control
Figure 3 Long-term results for blood pressure, waist circumference and glucose-related outcomes (Means ± SEM presented). Presents
change in A) systolic blood pressure (SBP); B) diastolic blood pressure (DBP); C) waist circumference (WC); D) fasting plasma glucose (FG);
E) glycated hemoglobin (HbA1c); and F) homeostasis model for insulin resistance (HOMA-IR) over time. *p <0.05 (from post-hoc analyses using
the Bonferroni method) White triangles = intervention group; black circles = active control group.
Petrella et al. BMC Public Health 2014, 14:1082 Page 8 of 11
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drome and showed reductions in fasting plasma glucose
[22] the present study did not find positive effects on
fasting plasma glucose. HbA1C, which is a marker of
three-month glucose regulation, showed a different
trend with small, but significant reductions in the
mHealth intervention group at 24 and 52 weeks and a
transient reduction in the active control group at
24 weeks. Average values for both groups over the 52-
week period, however, remained within the clinically
defined healthy range, which may have limited the
potential for improvement. Both SBP and DBP, on the
other hand, were improved over the course of the 52-
week study, though the active control group had
greater improvements in SBP at 12 weeks compared to
the intervention group. This result is supported by a
recent meta-analysis that showed that internet-based
blood pressure control interventions were more effective
when they were at least six months in duration compared
to those of shorter duration [10]. Similar analyses have notbeen completed for smartphone interventions, but a lon-
ger time period may be required to elicit change. Since the
active control group received only the tailored exercise
prescription, these participants may have been more
focused on completing exercise sessions, while the
intervention group may have been initially overwhelmed
with the exercise prescription and mHealth technology.
Once their comfort with the mHealth monitoring protocol
increased, they may have changed their focus to the ex-
ercise prescription. Exercise compliance over the first
12 weeks was, however, similar between groups. Con-
trary to the hypothesis and results of similar interven-
tions [11] there were no between group differences in
SBP or DBP at 24 or 52 weeks. In another year-long
intervention study for patients with diabetes and un-
controlled hypertension, the intervention group, which
received immediate feedback regarding submitted blood
pressure measures, reduced daytime ambulatory SBP by
9 mmHg, while the control group who monitored blood
pressure but did not receive feedback, did not experience
A. B. C. 
E..D
Intervention Active Control
Figure 4 Long-term results for lipid-related outcomes and CRPhs (Means ± SEM presented). Presents change in A) high density lipoprotein
cholesterol (HDL); B) low density lipoprotein cholesterol (LDL); C) total cholesterol (T-Chol); D) triglycerides (TG); and E) high sensitivity C-reactive
protein (CRPhs) over time. *p <0.05 (from post-hoc analyses using the Bonferroni method) White triangles = intervention group; black circles =
active control group.
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portant component to mHealth interventions. Although
participants in our study were able to review past mea-
surements and trends on their own, tailored feedback
messages might have resulted in greater improvements
in metabolic risk factors in the mHealth intervention
group compared to the active control group.
mHealth has been suggested as an alternate or even re-
placement for traditional clinical management of chronic
disease risk factors [23,24]. Access and availability of care
could include mHealth solutions among patients and
health care providers. Such considerations currently lack
rigorous investigation. In this study, both the mHealth
intervention and active control groups showed improve-
ments in cardiometabolic risk factors over the course of
the study, highlighting the importance of exercise pre-
scription for cardiometabolic risk management. An in-
teresting finding in the present study was that, contrary
to the hypothesis, SBP was initially reduced (at 12-weeks)
to a greater extent in the active control group compared
to the mHealth technology intervention group, though
there was no difference between groups at 24 and 52 weeks
of follow-up. While more research is needed, it may be
that an exercise program alone should be prescribed at
the onset of risk management and mHealth could be
added as a tool to aid in long-term maintenance ofbehavior change. As discussed above, more sophisti-
cated applications involving immediate automated feed-
back may be more effective for supporting optimal
health behaviours. Additionally, with the exponentially
increasing number of health management applications
available for smartphones, clinicians and patients could
chose those that specifically suit management and life-
style needs and preferences.
Although the differences in change in cardiometabolic
risk status were similar between the mHealth intervention
and active control groups, this study provides insight to
guide design and implementation of future, more so-
phisticated mHealth applications, which may lead to
improved long-term management of chronic disease
risk factors. The ideal protocol for mHealth monitoring
remains unknown, though it is likely that it should be
tailored to suit individuals’ lifestyle preferences and risk
factor modification needs. Additionally, it is unclear
why the active control group reduced SBP at 12 weeks
while the mHealth intervention group did not realize
improvements until 24 weeks. While these findings
correspond with those from internet-based health
intervention studies, research is needed to examine the
underlying reasons for the extended timeline for SBP
reductions to enable implementation of interventions
for optimal risk management.
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In conclusion, there appears to be no clear advantage of
a mHealth-supported exercise intervention in patients
with increased cardiovascular risk, over an active control
group receiving the STEP™ exercise prescription alone.
In fact, the STEP™ exercise prescription alone elicited
greater reductions in SBP after 12 weeks compared to
the mHealth intervention group. Over the long-term,
however, changes in SBP and other cardiometabolic risk
factors were equal between groups, suggesting that
short-term improvements in cardiometabolic risk may
be more effective with simpler interventions, but long-
term improvements can be realized with both exercise
prescription and mHealth supported exercise prescrip-
tion. Perhaps an exercise prescription following the
STEP™ protocol is best to achieve the initial SBP reduc-
tion and then mHealth tracking could be offered as an
assistive tool for interested patients or for patients in
need of monitoring for control of other diseases such as
hypertension or pre-diabetes.
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